Ten63 Therapeutics Launches BEYOND-Alpha Program with Chugai Pharmaceutical as First Participant
Trendline

Ten63 Therapeutics Launches BEYOND-Alpha Program with Chugai Pharmaceutical as First Participant

What's Happening? Ten63 Therapeutics, Inc., a company specializing in AI drug discovery, has announced the launch of BEYOND-Alpha, an early adopter program designed to scale its BEYOND computational drug design platform. Chugai Pharmaceutical Co., Ltd. is the first pharmaceutical company to particip
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.